Table 3. Analysis of 19 lipid mediators, which concentrations in synovial fluids from patients with rheumatoid arthritis were significantly higher than the concentrations in synovial fluids from patients with osteoarthritis based on a receiver operator characteristic curve analysis.

Acid	Major pathway	Mediator	Cutoff (pmol/mL)	Sensitivity (%)	Specificity (%)	p value	Positive likelihood ratio	Negative likelihood ratio
AA	COX	PGF2α	1.124	55.56	92.31	0.0357	7.225	0.481
	5-LO	5-HETE	63.61	66.67	96.15	0.0007	17.317	0.347
		5-oxo-ETE	0.05	22.22	100	0.215	Infinity	0.778
		LTB4	9.065	61.11	80.77	0.015	3.178	0.481
	15-LO	LXA4	2.474	61.11	100	0.0009	Infinity	0.389
		LXB4	2.33	61.11	92.31	0.0033	7.947	0.421
	12-LO	12-HETE	4.028	66.67	100	<0.0001	Infinity	0.333
	P450	8,9-EET	2.912	61.11	100	0.0011	Infinity	0.389
EPA	5-LO	5-HEPE	16.24	66.67	92.31	0.0021	8.670	0.361
		LTB5	0.065	37.5	96.15	0.12	9.740	0.650
	12-LO	12-HEPE	1.982	61.11	100	0.0045	Infinity	0.389
		8-HEPE	1.258	66.67	92.31	0.0019	8.670	0.361
DHA	COX	4-HDoHE	53.38	66.67	100	0.0019	Infinity	0.333
		7-HDoHE	2.02	61.11	100	0.0017	Infinity	0.389
		10-HDoHE	1.369	66.67	96.15	0.0016	17.317	0.347
	5-LO	13-HDoHE	7.669	66.67	96.15	0.0012	17.317	0.347
	15-LO	PD1	1.761	61.11	100	0.0005	Infinity	0.389
		17-HDoHE	4.966	66.67	96.15	0.0002	17.317	0.347
		20-HDoHE	53.49	66.67	100	0.0016	Infinity	0.333

AA, arachidonic acid; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; COX, cyclooxygenase; LO, lipoxygenase; PG, prostaglandin; HETE, hydroxyeicosatetraenoic acid; EET, epoxyeicosatrienoic acids; ETE, eicosatetraenoic acid; HDoHE, hydroxydocosahexaenoic acid; HEPE, hydroxyeicosapentaenoic acid; LT, leukotriene; LX, lipoxin; PD1, protectin D1; P450, cytochrome p450.